MicroTech closed-loop artificial pancreas
MicroTech Medical
What it is
MicroTech is developing a closed-loop system alongside its Equil pumps and CGM portfolio. Current manufacturer sources establish the program’s existence, but not a launch date, approved configuration or T1D efficacy results.
Editorial review: . What was checked and what remains uncertain.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Time in range: Provisional editorial assessment under substantial uncertainty. No numerical T1D time-in-range result substantiated.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the record-specific review limits for gaps in evidence, source access or availability checks.
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 35 × 20 + 35 × 20 + 35 × 10 + 35 × 20 + 35 × 5 + 35 × 5 + 35 × 5 + 35 × 5 + 0 × 10 = 3150; divide by total weight 100. Unrounded weighted result: 31.5.
Provisional editorial assessment under substantial uncertainty. No numerical T1D time-in-range result substantiated.[1]
Provisional editorial assessment under substantial uncertainty. No quantified hypoglycemia benefit or severe-event dataset substantiated.[1]
Provisional editorial assessment under substantial uncertainty. Manufacturer is developing integration of its CGM and pump; exact automation level unconfirmed.[1]
Provisional editorial assessment under substantial uncertainty. Wearable portfolio provides a possible foundation; final hardware pairing unconfirmed.[1]
Provisional editorial assessment under substantial uncertainty. No mean glucose, HbA1c or GMI outcome substantiated.[1]
Provisional editorial assessment under substantial uncertainty. No glycemic variability outcome substantiated.[1]
Provisional editorial assessment under substantial uncertainty. No exercise-handling outcome substantiated.[1]
Provisional editorial assessment under substantial uncertainty. Final settings and compatible components unconfirmed.[1]
AID default: 50% glucose outcomes and low-glucose protection, 40% daily experience, 10% access and cost. Freedom includes tubing, wearability, water-use limits and controller requirements. These are editorial priorities; studies and device generations differ. Check each scorecard for its evidence and limits.
Editor’s take
Included so a real manufacturer program is visible. Its provisional scores are editorial judgments under uncertainty, not clinical measurements or assumed equivalence to existing AID.
The full picture
MicroTech’s June2026 product update distinguishes its existing LinX CGM and Equil patch pump from a developing artificial-pancreas system. Its dedicated program page says “Coming Soon” without supplying a date or a clinical dataset.12
This establishes an active manufacturer development claim. It does not establish which sensor or pump version will be used, an approved AID configuration, fully closed-loop operation, pediatric eligibility or superior glucose control. These remain open questions; the provisional editorial scores do not fill those evidence gaps.
References
-
MicroTech June2026 update. https://www.microtechmd.com/about/news/2729 ↩
-
MicroTech program page. https://www.microtechmd.com/products/closed-loop-artificial-pancrea ↩
Coming soon
ETA · Timing and regulatory status not established
Sources
- [1]MicroTech June2026 development update · manufacturer
- [2]MicroTech closed-loop program page · manufacturer